Insulet (NASDAQ:PODD) Given New $170.00 Price Target at JPMorgan Chase & Co.

Insulet (NASDAQ:PODD) had its price target raised by research analysts at JPMorgan Chase & Co. from $152.00 to $170.00 in a note issued to investors on Thursday, Benzinga reports. The brokerage presently has a “neutral” rating on the medical instruments supplier’s stock. JPMorgan Chase & Co.‘s target price would suggest a potential upside of 8.89% from the company’s previous close.

Several other research firms also recently weighed in on PODD. Robert W. Baird set a $175.00 price target on Insulet in a research note on Thursday, August 6th. Wells Fargo & Company boosted their price objective on Insulet from $144.00 to $172.00 and gave the company an “equal weight” rating in a research note on Thursday. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Insulet in a report on Monday, September 21st. TD Cowen reaffirmed a “hold” rating on shares of Insulet in a report on Wednesday. Finally, Wall Street Zen lowered shares of Insulet from a “buy” rating to a “hold” rating in a research report on Saturday, October 24th. Thirteen analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Insulet currently has a consensus rating of “Hold” and an average target price of $191.52.

Insulet Stock Performance

Shares of PODD stock traded down $8.90 during trading on Thursday, hitting $156.12. The company’s stock had a trading volume of 1,319,217 shares, compared to its average volume of 1,397,991. The company has a market cap of $10.83 billion, a PE ratio of 29.18, a P/E/G ratio of 1.22 and a beta of 1.06. The company has a current ratio of 2.48, a quick ratio of 1.83 and a debt-to-equity ratio of 0.65. The business has a fifty day moving average of $141.65 and a 200-day moving average of $178.00. Insulet has a 52 week low of $126.40 and a 52 week high of $354.88.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Wednesday, November 4th. The medical instruments supplier reported $1.99 earnings per share for the quarter, topping the consensus estimate of $1.59 by $0.40. Insulet had a return on equity of 29.29% and a net margin of 12.29%. The business had revenue of $842.00 million for the quarter, compared to analysts’ expectations of $832.63 million. During the same quarter in the previous year, the firm earned $1.24 earnings per share. The business’s revenue was up 19.2% on a year-over-year basis. As a group, research analysts anticipate that Insulet will post 6.51 earnings per share for the current year.

Institutional Investors Weigh In On Insulet

Large investors have recently added to or reduced their stakes in the business. Elevation Wealth Partners LLC increased its holdings in shares of Insulet by 115.6% during the third quarter. Elevation Wealth Partners LLC now owns 194 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 104 shares in the last quarter. Activest Wealth Management increased its position in Insulet by 186.3% during the third quarter. Activest Wealth Management now owns 229 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 149 shares during the last quarter. WPG Advisers LLC boosted its holdings in shares of Insulet by 169.3% in the third quarter. WPG Advisers LLC now owns 272 shares of the medical instruments supplier’s stock worth $35,000 after buying an additional 171 shares during the last quarter. Covestor Ltd boosted its stake in shares of Insulet by 103.9% during the 3rd quarter. Covestor Ltd now owns 310 shares of the medical instruments supplier’s stock worth $40,000 after acquiring an additional 158 shares during the last quarter. Finally, Continuum Advisory LLC bought a new stake in Insulet during the second quarter valued at about $46,000.

Trending Headlines about Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet reported Q3 earnings of $1.99 per share, topping the $1.59 consensus, while revenue rose 19.2% year over year to $842 million and also beat estimates. The company raised its 2026 outlook and announced a $1 billion share-repurchase program. Insulet CEO Sees Slower Growth in 2027
• Positive Sentiment: Several analysts raised price targets after the results. RBC lifted its target to $180 and retained an Outperform rating; Bernstein raised its target to $200 and also rated the stock Outperform. RBC Raises Price Target
• Neutral Sentiment: Other firms also increased targets, including Citi to $170, Leerink Partners to $167, Wells Fargo to $172 and UBS to $171, but kept Neutral, Market Perform or Equal Weight ratings. RBC sees an attractive valuation, while noting a more conservative 2027 outlook. Insulet Sees Attractive Valuation
• Negative Sentiment: Management expects slower growth in 2027 and anticipates rivals will take some share from its Omnipod product. That forward-looking caution appears to be weighing on the stock despite the strong quarter. Insulet CEO Sees Slower Growth in 2027

About Insulet

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.